<DOC>
	<DOCNO>NCT01127555</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety mFOLFOX ( 5-fluorouracil , leucovorin , oxaliplatin ) salvage therapy patient unresectable biliary tract cancer fail gemcitabine .</brief_summary>
	<brief_title>Salvage mFOLFOX BTC After Failure Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age : old 18 2 . Histologically confirm adenocarcinoma biliary tract 3 . Metastatic unresectable biliary cancer 4 . Prior exposure gemcitabine chemotherapy biliary cancer 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 6 . A patient least one measurable primary lesion diameter confirm 10mm spiral Computed Tomography ( CT ) multidetector CT 7 . Adequate bone marrow , liver , renal function 1 . Pregnancy breastfeed . 2 . Other serious illness medical condition , notably heart lung failure , active uncontrolled infection ( infection require antibiotic ) . 3 . Past concurrent history neoplasm , except curatively treat basal cell skin cancer adequately treat insitu carcinoma cervix . 4 . Symptomatic uncontrolled brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Biliary Tract Cancer</keyword>
	<keyword>Salvage therapy</keyword>
	<keyword>FOLFOX</keyword>
</DOC>